Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD036 in Obstructive Sleep Apnea
NCT03845023Phase 2Completed
- Sponsor
- Apnimed, Inc.
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine and oxybutynin in obstructive sleep apnea (OSA), sponsored by Apnimed, Inc. Primary endpoint: Apnea Hypopnea Index. Started Mar 2019; status: completed.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03845023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845023.